Evidence map›Paper›PMID 25594062›Full record

ArticleOncoscience2014

Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.

Agata M Wasik, Lina Nygren, Stefan Almestrand, Fang Zong, Jenny Flygare, Stefanie Baumgartner Wennerholm, Leonie Saft, Patrik Andersson, Eva Kimby, Björn E Wahlin and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oncoscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. CNR1 and CNR2 Cannabinoid Receptor Mutations in Cancer Cells.Current issues in molecular biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Cannabinoid receptors in mantle cell lymphoma.Cell cycle (Georgetown, Tex.) · 2015
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Agata M WasikDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Lina NygrenDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Stefan AlmestrandDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Fang ZongDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Jenny FlygareDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Stefanie Baumgartner WennerholmDivision of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, SE 141 86 Stockholm, Sweden.
Leonie SaftClinical Pathology, Karolinska University Hospital Solna, SE 171 76 Stockholm, Sweden.
Patrik AnderssonDepartment of Hematology, Stockholm South Hospital, SE 118 83 Stockholm, Sweden.
Eva KimbyDivision of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, SE 141 86 Stockholm, Sweden.
Björn E WahlinDivision of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, SE 141 86 Stockholm, Sweden.
Birger ChristenssonDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Birgitta SanderDivision of Pathology, Department of Laboratory Medicine, Karolinska Institutet, SE 141 86 Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEStockholm South General Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cannabinoid receptors are upregulated in many types of cancers, including mantle cell lymphoma (MCL) and have been suggested to constitute novel therapeutic targets. The expression pattern of the key members of the endocannabinoid system was analyzed in a well-characterized MCL patient cohort and correlated to biological features. 107 tumor tissues were analyzed for the mRNA levels of cannabinoid receptors 1 and 2 (CNR1 and CNR2) and the two main enzymes regulating the endocannabinoid anandamide levels in tissue: NAPEPLD and FAAH (participating in synthesis and degradation, respectively). NAPEPLD, CNR1 and CNR2 were overexpressed while FAAH expression was reduced in MCL compared to non-malignant B-cells. Both low CNR1 and high FAAH levels correlated with lymphocytosis (p=0.016 and p=0.022, respectively) and with leukocytosis (p=0.0018 and p=0.047). Weak to moderate CNR1 levels were a feature of SOX11 negative MCL (p=0.006). Both high CNR2 and high FAAH levels correlated to anemia (p=0.0006 and p=0.038, respectively). In conclusion, the relative expression of the anandamide synthesizing and metabolizing enzymes in MCL is heavily perturbed. This finding, together with high expression of cannabinoid receptors, could favor enhanced anandamide signaling and suggest that targeting the endocannabinoid system might be considered as part of lymphoma therapy.

Indexed as

endocannabinoid systemmantle cell lymphoma

Identifiers

PMID25594062
PMCPMC4278325
OpenAlexW2150698449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.